Turner Jenkins
Managing Director, Beyond Celiac Investments Beyond Celiac
Turner is a seasoned executive with over 15 years of experience serving in several leadership roles in the biopharmaceutical industry, spanning venture capital, corporate development, and strategic alliance management across early-stage private venture backed to public commercial organizations. Previously, Turner held senior roles at Mirati Therapeutics (acquired by Bristol Myers Squibb), Curzion Pharmaceuticals (acquired by Horizon Therapeutics), and Regulus Therapeutics (acquired by Novartis). Turner has two children with celiac and knows firsthand the burden the disease has on patients and family members. He is passionate about advancing treatments towards a cure. Turner earned a B.S. degree in Chemical Engineering from UCLA and an MBA from the Rady School of Management at UCSD
Seminars
Review current levels of pharma and investor engagement with antigen-specific approaches to identify what would strengthen confidence in the space and positioning the field to attract deeper investment going forward.
- Understand what Big Pharma considers a commercially attractive indication and how they come to this decision to inform biotechs of what steps can support successful commercialization
- Discussing the type of data and evidence pharma and investors have indicated they want to see to clarify the gap between what is currently available and what may be expected, and explore how early-stage programs can prepare for this
- Considering how indication choice and commercial viability factor into investment decisions, to weigh biological rationale against practical, market-driven considerations, and inform how programs might frame their own value proposition
